You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Epoetin alfa-epbx - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for epoetin alfa-epbx
Tradenames:1
High Confidence Patents:0
Applicants:1
BLAs:1
Suppliers: see list2
Pharmacology for epoetin alfa-epbx
Physiological EffectIncreased Erythroid Cell Production
Established Pharmacologic ClassErythropoiesis-stimulating Agent
Chemical StructureErythropoietin
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for epoetin alfa-epbx Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for epoetin alfa-epbx Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for epoetin alfa-epbx Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Epoetin Alfa-epbx

Introduction to Epoetin Alfa-epbx

Epoetin alfa-epbx, marketed as Retacrit, is a biosimilar of epoetin alfa, a biologic drug used to treat anemia associated with chronic kidney disease (CKD), HIV infection, and certain types of cancer. Here, we delve into the market dynamics and financial trajectory of this crucial biologic agent.

Market Share and Adoption

As of Q3 2024, Retacrit, the biosimilar of epoetin alfa, maintains about a third of the epoetin alfa market share. The reference products, Epogen and Procrit, still hold a significant combined share of approximately 70% by matching the Average Sales Price (ASP) of the biosimilars[1].

Price Trends and Erosion

The ASP of epoetin alfa products has seen significant erosion. For instance, the ASP of Retacrit and other epoetin alfa biosimilars has declined substantially, with Retacrit's ASP aligning closely with that of the reference products to retain market share[1].

Competitive Landscape

The erythropoietin stimulating agents (ESAs) market is highly competitive, with several key players. Amgen, with its products Epogen and Procrit, is a major player, while Pfizer's Retacrit also holds a significant position. The market is further segmented by the emergence of biosimilars, which are gaining traction due to their cost-effectiveness[4].

Biosimilar Impact

Biosimilars, including Retacrit, are reshaping the ESA market by offering more affordable alternatives. The increasing adoption of biosimilars is driven by regulatory reforms that streamline approval processes, enhancing market competition and reducing costs. This trend is expected to continue, making ESA treatments more accessible globally[3][4].

Regional Market Dynamics

North America is the largest market segment for ESAs, driven by well-established healthcare infrastructures and high awareness levels. However, the Middle East and Africa are emerging as the fastest-growing regions, fueled by increasing healthcare investments and growing awareness of ESA treatments[4].

Growth Drivers and Trends

  • Increasing Prevalence of Chronic Kidney Diseases and Cancer-Related Anemia: The rising incidence of these conditions globally is driving the demand for erythropoietin drugs[3].
  • Growing Adoption of Biosimilars: The cost-effectiveness and increasing acceptance of biosimilars are key growth drivers[3][4].
  • Technological Advancements: Innovations in drug delivery systems and precision medicine are optimizing treatment efficacy and minimizing adverse effects[3].
  • Expansion of Indications: Erythropoietin drugs are being explored for use beyond anemia management, including in oncology and rheumatology[3].

Financial Projections

The global erythropoietin drugs market, including epoetin alfa-epbx, is projected to reach USD 14.3 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 3.8% from 2024 to 2034. This growth is driven by the increasing prevalence of chronic diseases, the adoption of biosimilars, and advancements in healthcare infrastructure[3].

Safety and Efficacy Considerations

Epoetin alfa-epbx, like other ESAs, carries significant safety risks, including increased risks of death, myocardial infarction, stroke, and venous thromboembolism. Clinical trials have shown adverse cardiovascular reactions and tumor progression or recurrence in certain patient groups. Therefore, careful patient selection and monitoring are crucial[2][5].

Regulatory Environment

Regulatory reforms aimed at streamlining the approval processes for biosimilars and biologics are fostering market competition. This environment is expected to continue driving down costs and enhancing accessibility to erythropoietin therapy globally[3].

Key Takeaways

  • Market Share: Retacrit holds about a third of the epoetin alfa market share, with the reference products maintaining a significant share.
  • Price Trends: Significant price erosion has been observed, with biosimilars matching the ASP of reference products.
  • Growth Drivers: Increasing prevalence of chronic diseases, adoption of biosimilars, and technological advancements are key growth drivers.
  • Financial Projections: The global erythropoietin drugs market is projected to reach USD 14.3 billion by 2034.
  • Safety Considerations: ESAs, including epoetin alfa-epbx, carry significant safety risks that require careful patient management.

FAQs

Q: What is the current market share of Retacrit in the epoetin alfa market? A: As of Q3 2024, Retacrit maintains about a third of the epoetin alfa market share[1].

Q: How has the ASP of epoetin alfa products changed over time? A: The ASP of epoetin alfa products has seen significant erosion, with biosimilars matching the ASP of reference products to retain market share[1].

Q: What are the key growth drivers for the erythropoietin drugs market? A: The key growth drivers include the increasing prevalence of chronic diseases, growing adoption of biosimilars, and technological advancements[3].

Q: What are the safety risks associated with epoetin alfa-epbx? A: Epoetin alfa-epbx carries risks of death, myocardial infarction, stroke, and venous thromboembolism, among other adverse cardiovascular reactions[2][5].

Q: What is the projected market size for erythropoietin drugs by 2034? A: The global erythropoietin drugs market is projected to reach USD 14.3 billion by 2034, growing at a CAGR of 3.8% from 2024 to 2034[3].

Cited Sources

  1. Samsung Bioepis: Biosimilar Market Dynamics - SAMSUNG BIOEPIS, Q3 2024.
  2. Pfizer: RETACRIT (epoetin alfa-epbx) injection.
  3. GlobeNewswire: Erythropoietin Drugs Market Estimated to Reach USD 14.3 billion, Transparency Market Research Inc., September 18, 2024.
  4. Virtu Market Research: Erythropoietin Stimulating Agents Market | Size, Share, Growth | 2023.
  5. Pfizer Biosimilars Resource: RETACRIT® (epoetin alfa-epbx) product and reimbursement.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.